There could be at least two amyloid-clearing antibodies for Alzheimer’s disease on the market in the US next year if Eli Lilly and Company succeeds in its pursuit of accelerated approval for donanemab. Lilly said on 24 June that the US Food and Drug Administration granted a breakthrough therapy designation for donanemab based on Phase II results reported earlier this year and that, following the accelerated approval for Biogen, Inc./Eisai Co., Ltd.’s Aduhelm, it plans to file a biologic license application with the agency based on the Phase II data later this year.
Lilly’s Donanemab Could Be A Near-Term Aduhelm Competitor
Company Will File For Accelerated Approval
Lilly said it will seek accelerated approval in the US based on Phase II data for its amyloid-clearing antibody, potentially narrowing Biogen/Eisai’s newly approved therapy Aduhelm’s time on the market as the only disease-modifying Alzheimer’s drug.
More from Neurological
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.